Factbox - Bristol-Myers#39; $74 billion Celgene buy has investors looking for next deal

Raymond James analysts said in a research note that MA could happen this year involving companies focussed on the huge unmet need for treating the progressive fatty liver disease known as NASH (non-alcoholic steatohepatitis), which does not yet have any approved treatments.

from Moneycontrol Business News http://bit.ly/2Qqa83u